Millennium Velcade Has 50%-60% Of Third-Line Multiple Myeloma Market
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
Millennium’s Velcade captured 50% to 60% of the third-line multiple myeloma market in the second quarter, the firm reported July 22.
You may also be interested in...
Velcade Shows Edge In Phase III Multiple Myeloma Trial; Fails In Colorectal
Millennium plans to submit its Phase III Velcade (bortezomib) confirmatory trial in multiple myeloma in the second half of 2004.
FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011
Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011